论文部分内容阅读
目的:研究miR-342-3p在乳腺癌中的表达及与临床病理联系。方法:收集2008年1月～2012年8月乳腺癌手术患者组织标本共85例,使用实时荧光定量PCR检测miR-342-3p在乳腺癌组织中的表达情况,应用免疫组化的方法检测乳腺癌组织中雌激素受体(ER)、孕激素受体(PR)、Her-2及P53的表达。结果:miRNA-342-3p在Lumina型乳腺癌组织中高表达,在Her-2高表达型乳腺癌次之,在三阴性乳腺癌组织中表达最低,差异有统计学意义(P<0.05);miRNA-342-3p的表达与不同ER、Her-2及P53的表达相关,差异有统计学意义(P<0.05),在不同PR状态、不同年龄组、有无淋巴结转移及与肿瘤大小、组织分级和病理分期间,差异无统计学意义(P>0.05),癌与癌旁组织间无显著性差异(P>0.05)。结论:miR-342-3p在不同乳腺癌分子亚型中表达存在差异,可能成为乳腺癌尤其是三阴性乳腺癌治疗的新靶点。
Objective: To study the expression of miR-342-3p in breast cancer and its relationship with clinical pathology. Methods: A total of 85 cases of breast cancer patients from January 2008 to August 2012 were collected. The expression of miR-342-3p in breast cancer tissues was detected by real-time fluorescent quantitative PCR. The mammary gland was detected by immunohistochemical method. The expression of estrogen receptor (ER), progesterone receptor (PR), Her-2, and P53 in cancer tissues. RESULTS: miRNA-342-3p was highly expressed in Lumina breast cancer tissues, followed by Her-2 high-expression breast cancers, and lowest in triple-negative breast cancer tissues (P<0.05). The expression of -342-3p was correlated with the expression of different ER, Her-2 and P53 (P<0.05). The differences in PR status, different age groups, lymph node metastasis, tumor size and histological grade There was no significant difference between pathology and pathology (P>0.05), and there was no significant difference between cancer and adjacent tissue (P>0.05). Conclusion: There is a difference in the expression of miR-342-3p in different breast cancer molecular subtypes and it may be a new target for the treatment of breast cancer, especially triple negative breast cancer.